We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NASDAQ:AZN | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.27 | -0.34% | 78.25 | 65.00 | 86.91 | 79.45 | 78.08 | 78.48 | 5,878,523 | 05:00:07 |
From Jul 2023 to Jul 2024
By Chris Wack
Absci shares were up 27% at $2.21 after the company entered into a collaboration with AstraZeneca to deliver an AI-designed antibody against an oncology target.
The stock hit its 52-week low of $1.11 on Oct. 26, and is down 18% in the past 12 months.
Absci said this collaboration combines its Integrated Drug Creation platform with AstraZeneca's expertise in oncology with the goal of speeding up the discovery of a potential new cancer treatment candidate.
Absci will contribute its generative AI technology to deliver a therapeutic candidate antibody for a specified oncology target. The agreement includes an upfront commitment, R&D funding and milestone payments, in addition to royalties on product sales.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
December 04, 2023 10:26 ET (15:26 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
